Table of contents

  • Brand Names
  • Drug Combinations
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Dosage

Brand Names


Austria: Iruxolum Mono; Belgium: Iruxol Mono; Czech Republic: Iruxol Mono; Finland: Iruxol Mono; Greece: Iruxol Mono; Poland: Iruxol Mono; Slovakia: Iruxol Mono.

North America

Canada: Santyl; USA: Santyl, Xiaflex.

Latin America

Brazil: Iruxol Mono, Kollagenase.

Drug combinations

Collagenase and Chloramphenicol

Collagenase and Protease


Pharmacologic Category

Skin and Mucous Membrane Agents, Miscellaneous; Topical Debridement Enzyme. (ATC-Code: D03BA02).

Mechanism of action

Collagenase is an enzyme derived from the fermentation of Clostridium histolyticum capable of specifically hydrolyzing peptide bonds of undenatured and denatured collagen. Collagenase liquefies necrotic tissue without damaging collagen in healthy tissue or newly formed granulation tissue. In addition, it does not act on fat, fibrin, keratin, or muscle. Contributes towards the formation of granulation tissue and subsequent epithelization of dermal ulcers and severely burned areas. May remove substrates necessary for bacterial proliferation or may permit antibodies, leukocytes, and antibiotics better access to the infected area.

Therapeutic use

Debridement of necrotic tissue in dermal ulcers and severe burns.

Pregnancy and lactiation implications

Not known if distributed into human milk.

Unlabeled use


Hypersensitivity to collagenase or any component of the formulation.

Warnings and precautions

Debriding enzymes may increase the risk of bacteremia (risk of systemic bacterial infections). For external use only.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart